References
- ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
- KrauseDSVan EttenRATyrosine kinases as targets for cancer therapyN Engl J Med2005353217218716014887
- ChenMHKerkeläRForceTMechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeuticsCirculation20081181849518591451
- ForceTKrauseDSVan EttenRAMolecular mechanisms of car-diotoxicity of tyrosine kinase inhibitionNat Rev Cancer20077533234417457301
- ChoueiriTKSchutzFAJeYRosenbergJEBellmuntJRisk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trialsJ Clin Oncol201028132280228520351323
- ZhangWQLiTLiHEfficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trialsMed Sci Monit201415202666227625503781
- PetrelliFCabidduMBorgonovoKBarniSRisk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trialsAnn Oncol20122371672167922241897
- MonsuezJJCharniotJCVignatNArtigouJYCardiac side-effects of cancer chemotherapyInt J Cardiol2010144131520399520
- SenderowiczAMJohnsonJRSridharaRZimmermanPJusticeRPazdurRErlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreasOncology (Williston Park)2007211416961706 discussion 1706–1709, 1712, 171518247017
- NomaTLemaireANaga PrasadSVBeta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardio-protectionJ Clin Invest200711792445245817786238
- MeinardiMTGietemaJAvan der GraafWTCardiovascular morbidity in long-term survivors of metastatic testicular cancerJ Clin Oncol20001881725173210764433